Caricamento...
ERBB2-mutated metastatic non-small cell lung cancer: response and resistance to targeted therapies
ERBB2/HER2 has long been recognized as an oncogenic driver in some breast and gastro-esophageal cancers, in which amplification of this gene confers sensitivity to treatment with ERBB2 directed agents. More recently, somatic mutations in ERBB2 have been reported in 1–2% of patients with lung adenoca...
Salvato in:
| Pubblicato in: | J Thorac Oncol |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5402884/ https://ncbi.nlm.nih.gov/pubmed/28167203 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2017.01.023 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|